Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DRALSERP vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Depletes monoamines (serotonin, norepinephrine, dopamine) from central and peripheral nerve terminals by binding to and inhibiting the vesicular monoamine transporter 2 (VMAT2), impairing storage and leading to enzymatic degradation.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension,Psychotic disorders (especially in patients intolerant to neuroleptics),Huntington's chorea
Hypertension
0.25 mg orally once daily; may increase by 0.25 mg every 2 weeks to a maximum of 1 mg daily in divided doses.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life is 45 to 50 hours; clinically significant as drug accumulates with repeated dosing, requiring careful titration.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Primarily hepatic via CYP2D6, CYP1A2, and CYP3A4; active metabolite: reserpiline.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Primarily hepatic metabolism to inactive metabolites; less than 1% excreted unchanged in urine; approximately 10% eliminated in feces.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Approximately 96% bound to plasma proteins, primarily albumin.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Volume of distribution is approximately 200 L/kg; extensive tissue distribution, particularly to adipose tissue.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral bioavailability is 50% to 60% due to extensive first-pass metabolism.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
No specific adjustment required; use with caution in severe renal impairment.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), reduce dose by 50%.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not recommended for use in pediatric patients.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at 0.125 mg orally once daily; titrate slowly to avoid excessive sedation and hypotension.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
Risk of depression and suicidal ideation; contraindicated in patients with a history of depression, suicidal tendencies, or Parkinson's disease.
None
May cause severe depression, suicidal thoughts, and extrapyramidal symptoms; avoid in patients with history of peptic ulcer disease (increases gastric acid secretion); may cause nasal congestion, bradycardia, and hypotension; use caution during surgery due to increased vagal tone.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
History of depression or suicidal tendencies; active peptic ulcer disease; ulcerative colitis; patients receiving electroconvulsive therapy; concurrent MAO inhibitors; hypersensitivity.
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products, soy sauce, tap beer) as reserpine can potentiate pressor response. Limit caffeine intake. Taking with food may reduce GI upset.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Associated with increased risk of congenital malformations including cardiovascular and neural tube defects. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal hypotension. Avoid throughout pregnancy.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Excreted into breast milk; M/P ratio approximately 0.5. Potential for adverse effects in the infant, including bradycardia and sedation. Not recommended during breastfeeding.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No established safe dose; contraindicated in pregnancy. Clearance may increase in second and third trimesters, but no dose adjustment recommended due to teratogenicity.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
DRALSERP (reserpine) is an older antihypertensive that depletes catecholamines. Monitor for depression, especially in elderly. Onset slow (2-3 weeks). Avoid in patients with history of peptic ulcer disease due to increased gastric acid secretion. Combine with thiazide diuretic if necessary but watch for enhanced hypotensive effect.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed, usually once daily. Full effect may take several weeks.,Avoid driving or operating heavy machinery until you know how this medication affects you, as it may cause dizziness or drowsiness.,Report any symptoms of depression, such as persistent sadness, loss of interest, or changes in sleep or appetite.,This drug can cause nasal congestion, dry mouth, or weight gain. Notify your doctor if these are bothersome.,Avoid alcohol, as it may increase side effects like dizziness and drowsiness.,Do not use over-the-counter cold, allergy, or weight loss products without consulting your doctor, as they may interact.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DRALSERP vs ALDORIL D30, answered by our medical review team.
DRALSERP is a Antihypertensive that works by Depletes monoamines (serotonin, norepinephrine, dopamine) from central and peripheral nerve terminals by binding to and inhibiting the vesicular monoamine transporter 2 (VMAT2), impairing storage and leading to enzymatic degradation.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DRALSERP and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DRALSERP is: 0.25 mg orally once daily; may increase by 0.25 mg every 2 weeks to a maximum of 1 mg daily in divided doses.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DRALSERP and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DRALSERP is classified as Category C. First trimester: Associated with increased risk of congenital malformations including cardiovascular and neural tube defects. Second and third trimesters: Risk of fetal growth rest. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.